Pirepemat

Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease[1][2].

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

IRL752 displayed its highest in vitro affinities for 5-HT and NA-related targets[2].

IRL752 (3.7-100 µmol/kg, s.c.) has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reversed deficits resulting from hypomonoaminergic function[2]. Animal Model: Normal rats[2]. Dosage: 3.7-100 µmol/kg. Administration: s.c., 30 min prior to testing. Result: Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.

[1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease.

[2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419.